[Using terasosine (setegis) in the treatment of hyperactive urinary bladder in elderly women]

Terasosine study covered 36 females aged 61 to 76 years (mean age 70.1 +/- 0.5 years) with hyperactive urinary bladder (HAUB). Thirty patients received alpha1-adrenoblocker terasosine (setegis) in a dose 1 mg twice a day for 2 months, 6 females were given placebo. At baseline, in 1 and 2 months the patients self-estimated urination, urine incontinence, imperative voiding, quality of life, discomfort, treatment satisfaction. Two months of therapy reduced imperative voiding by 70%, number of episodes of ugent incontinence by 90%. Capacity of the bladder increased by 30%. The patients reported improved condition of their bladder, 3 times lower discomfort because of imperative symptoms, satisfaction with treatment reached 71%. Patients of the placebo group noticed no significant positive trend in the above parameters. 43% patients with maximal improvement and cure of urine incontinence had good long-term results.